Research presented at the 2022 American Society of Clinical Oncology Annual Meeting shows White patients with myelodysplastic syndrome (MDS) have worse overall survival outcomes than African American patients, contrary to previous findings in other cancer types.
Disparities in cancer care and outcomes between African American patients and White patients have been demonstrated in past studies, with African American patients often experiencing worse outcomes. Regarding myelodysplastic syndrome (MDS), however, an abstract presented at the 2022 American Society of Clinical Oncology Annual Meeting shows White patients to have worse overall survival (OS) outcomes than African Americans patients.
MDS encompasses a group of clonal myeloid neoplasms first defined as malignant in 2001. The causes of MDS are often unknown, but in some cases, it can occur secondary to mutations caused by cancer therapies or other external factors. MDS can also evolve into acute myeloid leukemia (AML). Considering that past studies have found African Americans to have worse outcomes than White patients in several solid tumor and hematological cancers, including AML, the current study aimed to characterize baseline traits and outcomes in patients with MDS.
Researchers analyzed data from the Survival, Epidemiology, and End Results (SEER) cancer registry to analyze outcomes in 37,564 patients aged 20 years or older with confirmed MDS between 2000 and 2013. Patients were stratified into low-, intermediate-, and high-risk disease groups.
A total of 34,543 White patients (91.9%) and 3021 Black patients (8.1%) were included in the study, which compared patients’ baseline characteristics, mortality rates per cause of death, and OS. The median ages at diagnosis were 76 and 71 years, respectively. There was a higher proportion of men in the White study population vs in the African American population (58% vs 49%). Further, more African American patients were considered low risk (22.8% vs 21.5%) and fewer patients were considered high risk (14.5% vs 16.3%).
The median OS for African American patients was 33 months vs 26 months in White patients, and they were shown to have a 21% reduced risk of MDS-related mortality (HR, 0.79; 95% CI, 0.76-0.83; P < .001). The most common causes of death in both patient cohorts was MDS/leukemia, cardiovascular disease, and other cancers. The relationship between race and OS remained statistically significant when baseline covariates were adjusted in a multivariate Cox proportional hazards regression model.
The study was limited by its retrospective nature; its reliance on data only available in SEER, and the lack of data on subtypes of MDS, which is a heterogenous group of clonal myeloid neoplasms. Even so, the finding that African American patients had better OS than White patients with MDS warrants further research, the authors conclude.
These data differ from prior research on the disparities between African American and White patients with hematological malignancies.
Reference
Lesegretain A, Laadem A, Fell G, Fathi AT. Comparison of demographics, disease characteristics, and outcomes between African American patients and White patients with myelodysplastic syndrome: a population-based study. Abstract presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022; Chicago, IL. Accessed June 22, 2022. Abstract 7051. https://meetings.asco.org/abstracts-presentations/208243
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More